With more than 100 next-generation biologics set to lose patent exclusivity in the next 15 years, there is widespread agreement that developing biosimilars for these therapies will benefit society as a whole.
Kimberly Salgado
Advertisement
Kimberly Salgado is Head of Centre for Biosimilar Drug Development, ICON plc.
Articles by Kimberly Salgado
Advertisement
Latest Updated Articles
The Evolving Cost-Benefit Landscape of Biosimilar Drug DevelopmentPublished: June 17th 2025 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
AI-Driven Organ-on-Chip Platforms Are Changing the Game in Bio/Pharma R&D
2
Welcome to CPHI Frankfurt 2025
3
Novartis–Avidity Biosciences Deal Highlights Next-Gen RNA Manufacturing Potential
4
Q&A: An Evolution in Enzyme Engineering with Zymvol’s Marina Cañellas
5
